Fungal infections are some of the most serious diseases, especially for children who have difficulty fighting off infection. Treating invasive candidiasis is difficult because some of the drugs used don’t always work to get rid of fungal infections. The purpose of this research study is to collect information about how invasive candidiasis is treated in children and follow which invasive candidiasis treatments work better than others. We hope that information from this study will be used to develop better treatments in the future.

The IPFN has ongoing clinical studies for pediatric patients with invasive fungal infections.

Fungal infections like candidiasis are some of the most serious diseases, especially for children who have difficulty fighting off infection. It is important that doctors diagnose candidiasis as soon as possible. Currently, the standard diagnosis for candidiasis is a blood culture, but that is often slow and can be inaccurate. There are newer blood tests (called biomarkers) for candidiasis. These tests are approved by the U.S. Food and Drug Administration (FDA), but have not been fully tested in children. Since it is impossible to know exactly which patients who are sick would go on to develop candidiasis, we want to determine if biomarker results are different in children that are only at high-risk for developing candidiasis versus children who go on develop candidiasis. We hope that information from this study will be used to diagnose candidiasis sooner.